Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm

This study has been terminated.
(Poor recruitment)
University of Western Ontario, Canada
Information provided by (Responsible Party):
Brian Yan, Lawson Health Research Institute Identifier:
First received: February 1, 2012
Last updated: November 1, 2016
Last verified: November 2016

Pancreatic cysts are becoming diagnosed more frequently due to the increased use and sensitivity of imaging. A subset of these cysts are pre-cancerous, therefore suggested treatment is surgery for removal. However, surgery involves significant risks and emerging opinion suggests that not all cysts need to be surgically removed. An alternative therapy would be ideal, in particular for those where surgical risk outweighs the benefits of resection. Ethanol and paclitaxel ablation of pancreatic cysts may be a viable alternative to surgical resection.

Our hypothesis is that ethanol with paclitaxel ablation is a safe and effective method for treatment in those with per-cancerous, mucinous pancreatic cysts.

Condition Intervention Phase
Mucinous Cystic Tumor With Moderate Dysplasia
Mucinous Cystadenoma of Pancreas
Mucinous Cystadenocarcinoma of Pancreas
Benign Neoplasm of Pancreas
Drug: Ethanol and Paclitaxel Injection
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: EUS Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm

Resource links provided by NLM:

Further study details as provided by Lawson Health Research Institute:

Primary Outcome Measures:
  • Efficacy: Cyst Resolution [ Time Frame: 6 months ]
    Proportion of patients without cysts at 6 months

  • Efficacy: Degree of Ablation [ Time Frame: 6 months ]
    Degree of cyst epithelial ablation in those undergoing resection

Secondary Outcome Measures:
  • Safety [ Time Frame: 30 day ]
    Safety of ethanol/paclitaxel ablation

  • Efficacy: Change of tumor markers [ Time Frame: 12 month ]
    Change of CEA level in those with persistent/recurrent cyst

  • Efficacy: Cyst Resolution [ Time Frame: 12 month ]
    Proportion of patients without cysts at 12 months

  • Efficacy: Cyst Resolution [ Time Frame: 18 months ]
    Proportion of patients without cysts at 18 months

  • Efficacy: Cyst Resolution [ Time Frame: 24 months ]
    Proportion of patients with no cysts at 24 months

Enrollment: 1
Study Start Date: September 2012
Study Completion Date: November 2016
Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ethanol and Paclitaxel Injection
All patients will receive at least one treatment with alcohol and paclitaxel.
Drug: Ethanol and Paclitaxel Injection
Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL [3mg/ml diluted in normal saline from original concentration of 6mg/mL] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
Other Names:
  • Ethanol
  • Paclitaxel


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Mucinous cystic neoplasm defined by cyst fluid analysis [23, 28]:

    • CEA > 192ng/mL
    • Amylase < 800 IU/L
    • Cytology negative for malignant cells
    • No communication of cyst with pancreatic duct on 2 imaging studies (EUS, CT, MRCP, or ERCP)
  2. Cyst size > 15mm but <50mm
  3. 3 or fewer cyst compartments
  4. Age ≥18 and ≤ 85

Exclusion Criteria:

  1. Inability to safely undergo EUS examination with standard conscious sedation
  2. Inability for safe FNA needle insertion into the cyst (eg: intervening vessel)
  3. Inability to undergo MRI (metal implants/cardiac pacemaker/defibrillator, claustrophobia)
  4. Coagulopathy (INR>1.5 or platelets<50)
  5. Active pancreatitis or pancreatic infection
  6. Active sepsis/bacteremia
  7. Inability to provide informed consent
  8. Pregnancy
  9. Breastfeeding women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01525706

Canada, Ontario
St. Joseph's Health Care
London, Ontario, Canada, N6A 4V2
Sponsors and Collaborators
Lawson Health Research Institute
University of Western Ontario, Canada
Principal Investigator: Brian M Yan, MD, FRCPC University of Western Ontario, Canada
  More Information

Responsible Party: Brian Yan, Assistant Professor of Medicine, Lawson Health Research Institute Identifier: NCT01525706     History of Changes
Other Study ID Numbers: UWO18494
Study First Received: February 1, 2012
Last Updated: November 1, 2016

Keywords provided by Lawson Health Research Institute:
Endoscopic Ultrasound
Pancreatic Mucinous Cystic Neoplasm
Fine Needle Injection
Ethanol Ablation
Paclitaxel Ablation

Additional relevant MeSH terms:
Cystadenocarcinoma, Mucinous
Pancreatic Neoplasms
Cystadenoma, Mucinous
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Cystic, Mucinous, and Serous
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants processed this record on May 22, 2017